• Yusuke Asada, Hideo Baba, Kazunori Tokizawa, Yutaka Ikeda, Chisato Takagi, Taku Fujii, Nobuhiko Okamoto, Kaoru Takeshima, Atsunori Asami, Kazuo Yamafuji, and Kiyoshi Kubochi.
• Dept. of Surgery, Saitama City Hospital.
• Gan To Kagaku Ryoho. 2020 Jul 1; 47 (7): 1109-1111.

AbstractWe present the case of a 75-year-old woman who received CapeOX plus Bmab therapy(capecitabine, oxaliplatin, and bevacizumab)after primary excision for an unresectable advanced sigmoid colon cancer with remote metastasis. Pneumatosis intestinalis(i.e., the presence of isolated gas in the abdominal cavity)was revealed accidentally during a periodical imaging examination in the small intestine and transverse colon, albeit no subjective symptoms were reported. Owing to the absence of definitive evidence of pneumatosis intestinalis and gastrointestinal perforation, the patient was diagnosed with idiopathic pneumatosis intestinalis. Bmab was discontinued, and CapeOX therapy alone was continued after follow-up. Approximately 4 months later, pneumatosis intestinalis had completely disappeared. Bmab is a vascular endothelial growth factor antibody with well-known side effect of gastrointestinal-perforation. However, there have been few reports on pneumatosis intestinalis; to our knowledge, there have been no reports on pneumatosis intestinalis associated with colorectal cancer in Japan. Further, the report suggests the need for appropriate and immediate management of pneumatosis intestinalis following diagnosis.

10 keywords...

hide…